Stocks and Investing Stocks and Investing
Tue, November 2, 2021
Mon, November 1, 2021
Sun, October 31, 2021
Sat, October 30, 2021
Fri, October 29, 2021

Keay Nakae Maintained (ALNY) at Strong Buy with Increased Target to $200 on, Oct 29th, 2021


Published on 2024-10-27 18:24:49 - WOPRAI, Keay Nakae
  Print publication without navigation


Keay Nakae of Chardan Capital, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Strong Buy with Increased Target from $190 to $200 on, Oct 29th, 2021.

Keay has made no other calls on ALNY in the last 4 months.



There are 7 other peers that have a rating on ALNY. Out of the 7 peers that are also analyzing ALNY, 3 agree with Keay's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Increased Target to $108 on, Thursday, October 28th, 2021
  • Gary Nachman of "BMO Capital" Maintained at Hold with Increased Target to $196 on, Friday, August 27th, 2021
  • Edward Tenthoff of "Piper Sandler" Downgraded from Buy to Hold and Held Target at $181 on, Wednesday, August 4th, 2021


These are the ratings of the 4 analyists that currently disagree with Keay


  • Esther Rajavelu of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $215 on, Monday, October 4th, 2021
  • Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $250 on, Friday, August 13th, 2021
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $216 on, Wednesday, August 4th, 2021
  • David Lebovitz of "Morgan Stanley" Maintained at Buy with Increased Target to $234 on, Wednesday, August 4th, 2021